Therapeutic Plasma Exchange

Therapeutic Plasma Exchange

Global Therapeutic Plasma Exchange Market to Reach US$2.1 Billion by 2030

The global market for Therapeutic Plasma Exchange estimated at US$1.4 Billion in the year 2023, is expected to reach US$2.1 Billion by 2030, growing at a CAGR of 6.2% over the analysis period 2023-2030. Neurological Disorders Indication, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$789.6 Million by the end of the analysis period. Growth in the Renal Disorders Indication segment is estimated at 5.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$380.5 Million While China is Forecast to Grow at 5.7% CAGR

The Therapeutic Plasma Exchange market in the U.S. is estimated at US$380.5 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$331.7 Million by the year 2030 trailing a CAGR of 5.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.5% and 5.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.6% CAGR.

Global Therapeutic Plasma Exchange Market - Key Trends and Drivers Summarized

What Makes Therapeutic Plasma Exchange Critical in Modern Healthcare?

Therapeutic plasma exchange (TPE) has emerged as a life-saving procedure in treating various autoimmune diseases, hematological conditions, and neurological disorders. This procedure involves the removal of plasma from a patient`s blood and its replacement with fresh plasma or a plasma substitute, which helps eliminate harmful antibodies and toxins. The increasing use of TPE in treating conditions such as Guillain-Barré syndrome, myasthenia gravis, and multiple sclerosis has underscored its critical role in healthcare. As awareness of the benefits of plasma exchange grows, more patients and healthcare providers are turning to this therapy, which has significantly expanded the therapeutic plasma exchange market in recent years.

How Are Different Applications and Technologies Driving the Market?

By technology, centrifugal-based and membrane filtration techniques are the most commonly employed methods, each offering distinct advantages. Centrifugal-based systems are widely used in treating neurological conditions, whereas membrane filtration is preferred for renal disorders and certain hematological diseases. Disease indication segments range from autoimmune disorders to blood dyscrasias and other critical illnesses. In terms of end-users, hospitals, specialty clinics, and blood donation centers dominate the market, with a growing number of outpatient facilities adopting TPE procedures for chronic disease management. The rising number of treatment options that incorporate TPE is expanding the market’s overall reach.

What Innovations Are Shaping the Future of Therapeutic Plasma Exchange?

Technological advancements have led to more efficient, safe, and user-friendly plasma exchange systems, making the procedure more accessible to healthcare providers. Automated apheresis devices, equipped with enhanced safety features, are increasingly becoming the standard of care, reducing procedure time and improving patient outcomes. Moreover, the integration of real-time monitoring and data analytics in TPE systems allows healthcare providers to customize treatments based on patient-specific conditions. Additionally, the growing trend of combining therapeutic plasma exchange with other treatment modalities, such as immunosuppressive therapies, is transforming the landscape of chronic disease management.

What Are the Key Drivers of Growth in the Therapeutic Plasma Exchange Market?

The growth in the therapeutic plasma exchange market is driven by several factors, including the rising prevalence of autoimmune diseases, the increased use of TPE in treating neurological conditions, and the growing number of regulatory approvals for novel plasma exchange devices. Technological innovations in apheresis devices, coupled with rising investments in healthcare infrastructure, are expanding the adoption of TPE. Additionally, increasing awareness among healthcare professionals about the benefits of early intervention with TPE in critical care settings is boosting the demand for plasma exchange. The expanding base of patients eligible for TPE, particularly in the treatment of rare and complex disorders, further propels market growth. Lastly, the development of portable and more cost-effective plasma exchange systems is expected to make this life-saving therapy more accessible, driving market expansion in the coming years.

Select Competitors (Total 47 Featured) -

• Asahi Kasei Medical Co., Ltd.
• B. Braun Melsungen AG
• Baxter International, Inc.
• Fenwal, Inc.
• Fresenius SE & Co. KGaA
• Haemonetics Corporation
• HemaCare Corporation
• Kawasumi Laboratories, Inc.
• Terumo BCT, Inc.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.